Myfortic (Mycophenolic Acid)

Mycophenolic acid selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides. By limiting this pathway, the drug reduces the proliferation of activated T and B lymphocytes, thereby dampening the immune response that can attack a transplanted organ.

The dosage of Myfortic is individualized. A qualified prescriber determines the appropriate dose based on the type of transplant, patient weight, renal function, and other concurrent medications. Patients should follow the prescribing physician’s instructions and not adjust the dose on their own.

The safety of Myfortic in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting or continuing therapy.

To request Myfortic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Myfortic (mycophenolic acid) differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcineurin signaling. This distinct mechanism can provide complementary immunosuppression and may be preferred when clinicians aim to reduce nephrotoxicity associated with calcineurin agents.

Myfortic tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack. Keep the medication away from moisture, heat, and direct sunlight to maintain stability and potency.

Myfortic is taken orally as an enteric‑coated tablet. It is usually swallowed whole with water, preferably on an empty stomach or as directed by the prescribing physician to ensure optimal absorption.

Serious risks include leukopenia (low white‑blood‑cell count), severe infections, liver toxicity, and an increased long‑term risk of certain malignancies. Patients should be monitored regularly for blood‑cell counts, liver function, and signs of infection.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should be used with caution in individuals with severe renal impairment, active infections, or those receiving live vaccines, and only under close medical supervision.